<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03092934</url>
  </required_header>
  <id_info>
    <org_study_id>17228</org_study_id>
    <secondary_id>AURA-001</secondary_id>
    <secondary_id>J1O-MC-JZHA</secondary_id>
    <nct_id>NCT03092934</nct_id>
  </id_info>
  <brief_title>A Study of AK-01 (LY3295668) in Solid Tumors</brief_title>
  <official_title>A Phase I/II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of AK-01 as Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AurKa Pharma Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This two-part study consists of a phase 1 dose escalation study in participants with locally
      advanced or metastatic solid tumors, and a phase 2 portion in up to 3 groups with either
      small cell lung cancer, breast cancer and/or one other solid tumor type.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 29, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open-Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (Phase 1)</measure>
    <time_frame>Up to approximately 4 months</time_frame>
    <description>Proportion of participants in a cohort with dose-limiting toxicities during Cycle 1, as defined by the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (Phase 2)</measure>
    <time_frame>Up to seven months</time_frame>
    <description>Proportion of partial or complete responders as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with One or More Treatment-Related Adverse Events (Phase 1)</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>Number of participants with untoward medical events associated with the use of a drug in humans, whether or not related to AURA-001</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with One or More Treatment-Related Adverse Events (Phase 2)</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>Number of participants with untoward medical events associated with the use of a drug in humans, whether or not related to AURA-001</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the Plasma Concentration-time Curve from Time Zero to 12 Hours Post-dose (AUC[0-12]) (Phase 2)</measure>
    <time_frame>Up to 12 hours</time_frame>
    <description>Area under the plasma concentration-time curve for AK-01 from time zero to 12 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve from Time Zero to 24 Hours Post-dose (AUC[0-24]) (Phase 2)</measure>
    <time_frame>Up to 24 hours post-dose</time_frame>
    <description>Area under the plasma concentration-time curve for AK-01 from time zero to 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) (Phase 2)</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>Maximum observed plasma concentration for AK-01</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Observed Plasma Concentration (Tmax) (Phase 2)</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>Time of maximum observed plasma concentration of AK-01</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Elimination Half-life (t1/2) (Phase 2)</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>Apparent terminal elimination half-life of AK-01</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Plasma Clearance (CL/F) (Phase 2)</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>Apparent total plasma clearance of AK-01</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) (Phase 2)</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>Apparent volume of distribution of AK-01</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in White Blood Cell Count</measure>
    <time_frame>Baseline, Up to 21 days</time_frame>
    <description>Change from baseline in white blood cell count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Neutrophil Count</measure>
    <time_frame>Baseline, Up to 21 days</time_frame>
    <description>Change from baseline in neutrophil count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Lymphocyte Count</measure>
    <time_frame>Baseline, Up to 21 days</time_frame>
    <description>Change from baseline in lymphocyte count</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Neoplasms</condition>
  <condition>Neoplasm Metastasis</condition>
  <condition>Triple Negative Breast Neoplasms</condition>
  <condition>Head and Neck Neoplasms</condition>
  <condition>Breast Neoplasms</condition>
  <condition>Solid Tumor, Adult</condition>
  <condition>Small Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>LY3295668 (Phase 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating doses ranging from 50 milligrams up to 1600 milligrams daily, administered orally in 21-day cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3295668 (Phase 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily dose level established in phase 1, administered orally in 21-day cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3295668</intervention_name>
    <description>Oral capsules</description>
    <arm_group_label>LY3295668 (Phase 1)</arm_group_label>
    <arm_group_label>LY3295668 (Phase 2)</arm_group_label>
    <other_name>AK-01</other_name>
    <other_name>Erbumine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have received at least 1 but no more than 4 prior systemic therapies

          -  Have adequate organ function

          -  Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)
             scale

          -  Have estimated life expectancy greater than or equal to (â‰¥)12 weeks

          -  Have fully recovered from radiation therapy or surgery, and are recovering from any
             acute adverse effects of other cancer therapies

          -  Have discontinued all chemotherapy, investigational therapy, molecularly-targeted
             therapy, and cancer-related hormonal therapy at least 14 days prior, biologic or
             immunotherapeutic therapy at least 21 days prior, or mitomycin-C or nitrosoureas at
             least 6 weeks prior

          -  Female participants with reproductive potential agree to use 2 forms of highly
             effective contraception during the study and for the following 3 months

          -  Male participants must use a barrier method of contraception during the study and for
             the following 3 months

        Phase 1

          -  Have evidence of a solid tumor that is locally advanced and/or metastatic (excluding
             primary brain tumor)

        Phase 2

          -  Have disease measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1

          -  Have evidence of a solid tumor that is locally advanced and/or metastatic, and in:

               -  Small Cell Lung Cancer (SCLC), must have failed platinum-containing therapy

               -  Breast Cancer, be Estrogen Receptor positive and/or Progesterone Receptor
                  positive, but Human Epidermal Growth Factor Receptor 2 (HER2) negative, and must
                  have failed a hormone therapy and a Cyclin-dependent kinase 4/6 (CDK4/6)
                  inhibitor

               -  Triple negative breast cancer (TNBC) and failed standard therapy

               -  Squamous cell cancers of the head neck associated with the human papilloma virus
                  (HPV), and have failed standard therapy

               -  Other solid tumor type that has been approved by the sponsor

        Exclusion Criteria:

          -  Have symptomatic central nervous system (CNS) metastasis (unless asymptomatic and not
             current receiving corticosteroids) or a primary tumor of the CNS

          -  Have a medical condition that precludes participation (swallowing disorder, organ
             transplant, pregnant or nursing, HIV, active Hepatitis B or C, cardiac disease,
             history of major surgery in upper gastrointestinal (GI) tract or GI disease,
             hypokalemia, hypomagnesaemia or hypocalcaemia that cannot be controlled)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <removed_countries>
    <country>Ukraine</country>
  </removed_countries>
  <verification_date>August 15, 2019</verification_date>
  <study_first_submitted>March 22, 2017</study_first_submitted>
  <study_first_submitted_qc>March 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2017</study_first_posted>
  <last_update_submitted>August 26, 2019</last_update_submitted>
  <last_update_submitted_qc>August 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

